Close

Anti-CD72 (4G4) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-0120ZP2714)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD72 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD72. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD72 antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Breast cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD72
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • Breast cancer
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-4-1BB-CD3ζ
  • Discription of Signaling Cassetes
  • 4-1BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 4G4
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CD72
  • Synonyms
  • LYB2; CD72b

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data Cyt

Fig.1 In vitro cytotoxicity of CAR cells.

CAR Construction : NbD4-41BB-CD3ζ Latest CAR Construction

Fig.1 In vitro cytotoxicity of CAR cells.

Three B-ALL cell lines (SEM, RS411, and NALM6) and three lymphoma cell lines (TOLEDO-DLBCL, Namalwa-Burkitt lymphoma, and JEKO-mantle cell lymphoma) evaluated susceptibility to either CD19 or CD72-directed CAR T cytotoxicity.

Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y. H. T., Rivera, J. M., ... & Wiita, A. P. (2021). Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALLCD72 Nanobody-Based CAR-T in MLLr B-ALL. Cancer discovery, 11(8), 2032-2049.

Complete CAR data FuncS

Fig.2 Determination of cytokines release.

CAR Construction : NbD4-41BB-CD3ζ Latest CAR Construction

Fig.2 Determination of cytokines release.

Cytokines released by different CD8 CAR-T cells after 1:1 coculture for 24 hours with the SEM B-ALL cell line.

Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y. H. T., Rivera, J. M., ... & Wiita, A. P. (2021). Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALLCD72 Nanobody-Based CAR-T in MLLr B-ALL. Cancer discovery, 11(8), 2032-2049.

Complete CAR data FCM

Fig.3 CAR-T cell proliferation assay.

CAR Construction : NbD4-41BB-CD3ζ Latest CAR Construction

Fig.3 CAR-T cell proliferation assay.

Proliferation of CD4 and CD8 CAR-T cells cultured alone or at a 1:1 E:T ratio with either AMO1 tumor cells (multiple myeloma, CD19- and CD72- ) or SEM tumor cells (B-ALL, CD19+ and CD72+).

Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y. H. T., Rivera, J. M., ... & Wiita, A. P. (2021). Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALLCD72 Nanobody-Based CAR-T in MLLr B-ALL. Cancer discovery, 11(8), 2032-2049.

Complete CAR data BI

Fig.4 CD72 CAR-T cells eradicate tumors and prolong survival in cell line and xenograft models of B-ALL.

CAR Construction : NbD4-41BB-CD3ζ Latest CAR Construction

Fig.4 CD72 CAR-T cells eradicate tumors and prolong survival in cell line and xenograft models of B-ALL.

A: MLLr B-ALL PDX and were treated on day 10 with different CAR-T cells; B, SEM B-ALL cells, treated on day 3 with different CAR-T cells; C, CD19-negative SEM B-ALL cells, treated on day 3 with different CAR-T cells.

Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y. H. T., Rivera, J. M., ... & Wiita, A. P. (2021). Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALLCD72 Nanobody-Based CAR-T in MLLr B-ALL. Cancer discovery, 11(8), 2032-2049.

CAR scFv data SPR

Fig.5 The binding affinity measurement of NbD4 to CD72.

CAR Construction : Latest CAR Construction

Fig.5 The binding affinity measurement of NbD4 to CD72.

Biolayer interferometry demonstrated that NbD4 bound with surprisingly low affinity to recombinant CD72 (K D~800 nM), with both slow on rate (k on 8.38e4 M-1s-1) and rapid off rate (k off 6.82e-2s -1).

Nix, M. A., Temple, W. C., Karlon, W., Wang, D., Phojanakong, P., Steri, V., ... & Wiita, A. P. (2021). CD72 Nanobody-Based CAR-T Cells Have Potent Anti-Tumor Efficacy in B Cell Malignancies. Blood, 138, 1717.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD72 (4G4) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-0120ZP2714). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.